Compliance Rate

Compliance Rate 51.23%
Compliant submissions 187
Incompliant submissions 178
Total trials 365

My Organizations' Clinical Trials

Showing 2075 of 2400 entries
View as:

Cardamom and Topical Roseomonas in Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06096857 Org: User:
Start: 10/09/24 End: 01/01/26 Due: 01/01/27

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

Phase: N/A Priority: Normal
NCT ID: NCT03278912 Org: User:
Start: 09/08/23 End: 09/08/23 Due: 09/08/24

A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05627258 Org: User:
Start: 01/30/23 End: 07/17/24 Due: 07/17/25

Magnetic Resonance Imaging of the Face and Bones

Phase: N/A Priority: Normal
NCT ID: NCT00001762 Org: User:
Start: 02/23/98 End: 07/26/13 Due: 07/26/14

Chiron Corp HCV E1/E2 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT00500747 Org: User:
Start: 08/31/03 End: 08/31/05 Due: 08/31/06

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

Phase: N/A Priority: Normal
NCT ID: NCT00001026 Org: User:
Start: - End: 12/31/94 Due: 12/31/95

Collection of Specimens for Study of Inflammatory Bowel Disease

Phase: N/A Priority: Normal
NCT ID: NCT00086554 Org: User:
Start: 07/01/04 End: 01/08/10 Due: 01/08/11

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

Phase: N/A Priority: Normal
NCT ID: NCT00001045 Org: User:
Start: - End: 10/31/98 Due: 10/31/99

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Phase: N/A Priority: Normal
NCT ID: NCT00017719 Org: User:
Start: 05/31/02 End: 03/31/06 Due: 03/31/07

Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

Phase: N/A Priority: Normal
NCT ID: NCT00270257 Org: User:
Start: 05/31/08 End: 07/31/12 Due: 07/31/13

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02344290 Org: User:
Start: 03/26/15 End: 08/21/23 Due: 08/21/24

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT00796705 Org: User:
Start: 11/30/08 End: 10/31/10 Due: 10/31/11

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

Phase: N/A Priority: Normal
NCT ID: NCT04915768 Org: User:
Start: 01/23/23 End: 08/26/25 Due: 08/26/26

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Phase: N/A Priority: Normal
NCT ID: NCT06812494 Org: User:
Start: 03/07/25 End: 09/15/27 Due: 09/15/28

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00001282 Org: User:
Start: 07/31/91 End: 04/30/02 Due: 04/30/03

Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in Uganda

Phase: N/A Priority: Normal
NCT ID: NCT01109342 Org: User:
Start: 07/31/10 End: 06/30/12 Due: 06/30/13

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

Phase: N/A Priority: Normal
NCT ID: NCT00006066 Org: User:
Start: - End: 06/30/06 Due: 06/30/07

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Phase: N/A Priority: Normal
NCT ID: NCT00001044 Org: User:
Start: - End: 05/31/95 Due: 05/31/96

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

Phase: N/A Priority: Normal
NCT ID: NCT01314911 Org: User:
Start: 04/30/11 End: 11/18/17 Due: 11/18/18

Immune Responses to Smallpox Vaccination

Phase: N/A Priority: Normal
NCT ID: NCT00325975 Org: User:
Start: 02/04/03 End: 03/15/16 Due: 03/15/17

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

Phase: N/A Priority: Normal
NCT ID: NCT03387150 Org: User:
Start: 02/28/18 End: 12/07/20 Due: 12/07/21

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Phase: N/A Priority: Normal
NCT ID: NCT03719586 Org: User:
Start: 11/21/18 End: 08/18/20 Due: 08/18/21

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04843761 Org: User:
Start: 04/20/21 End: 11/20/22 Due: 11/20/23

Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States

Phase: N/A Priority: Normal
NCT ID: NCT02153996 Org: User:
Start: 05/15/14 End: 03/15/16 Due: 03/15/17

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Phase: N/A Priority: Normal
NCT ID: NCT02287467 Org: User:
Start: 01/31/15 End: 06/07/18 Due: 06/07/19